BPH treatment offers promising 2-year results
An investigational therapy for BPH known as NX-1207 has shown positive results in a long-term outcome study, according to its manufacturer, Nymox Pharmaceutical Corp.
An investigational therapy for BPH known as NX-1207 has shown positive results in a long-term outcome study, according to its manufacturer, Nymox Pharmaceutical Corp.
Twenty-four clinical trial sites across the United States and 103 unselected subjects participated in the blinded, placebo-controlled study.
The study assessed symptom scores and treatment outcome 2 years (range, 16 to 27 months) after a single treatment with NX-1207 or placebo. At the time of follow-up, 52% of patients treated with NX-1207 were not on BPH medication and had not required surgical intervention for their BPH since their initial treatment with NX-1207; these patients had a mean improvement of 10.2 points in AUA BPH Symptom Score values.
For patients with prostates <70 grams, the results showed that a statistically significant percentage of patients initially treated once with NX-1207 were not on BPH medication and had not required surgical intervention compared with patients who received placebo. In this population, the results showed that 60% of patients who received NX-1207 required no other BPH treatment and had maintained an improvement of 11.3 points in BPH symptom score (p<.05 vs. placebo).
